XM does not provide services to residents of the United States of America.
N
N

Novartis


News

China c.bank seen holding medium-term lending rate steady Monday

China c.bank seen holding medium-term lending rate steady Monday SHANGHAI/SINGAPORE, July 12 (Reuters) - China's central bank is widely expected to leave a medium-term interest rate unchanged and drain some cash from the banking system when rolling over such maturing loans on Monday, a Reuters survey showed. While the economy continues to sputter, a weak Chinese currency has remained the key constraint limiting Beijing's monetary easing efforts, as that could further widen the yield gap with oth
B
N

European companies cut jobs as economy sputters

FACTBOX-European companies cut jobs as economy sputters Adds details on fresh job cuts July 9 (Reuters) - Elevated levels of inflation and the impact of the war in Ukraine have forced companies across Europe to freeze hiring or cut jobs. Here are some layoffs announced since the start of April: BANKS * TSB: The British bank owned by Spain's Sabadell SABE.MC is seeking 250 job cuts and 36 branch closures, its spokesperson and employee union said on May 8. INDUSTRIALS AND ENGINEERING * METSO METSO
B
B
B
B
C
I
M
N
T
T
U
V
B
U

Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector

Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector COPENHAGEN, July 5 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9.97 million) between 2020 and 2022. The UK industry body Prescription Medicines Code of Practice Authority (PMCPA) said on Friday that the reprimand followed a voluntary submi
N
P

Pearson, Softcat, Trelleborg

EUROPE RESEARCH ROUNDUP- Pearson, Softcat, Trelleborg July 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Pearson, Softcat and Trelleborg, on Friday. HIGHLIGHTS * Aker BP ASA AKRBP.OL : Jefferies cuts target price to NOK 340 from NOK 345 * GSK GSK.L : Citigroup cuts target price to 1900p from 2120p * Pearson PSON.L : Deutsche Bank raises target price to 1052p from 1050p * Softcat Plc SCTS.L : Jefferies cuts target price to 1,490p
A
A
B
C
C
D
D
E
E
G
I
K
N
N
P
T
T
T
V
W
A
D
Y

A closer look at U.S. drug pricing risks

LIVE MARKETS-A closer look at U.S. drug pricing risks STOXX 600 up 0.8% Paris, Milan bourses outperform Fed rate cut bets support mood Wall St futures broadly unchanged Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com A CLOSER LOOK AT U.S.
A
A
E
N
U
E
F
I
U
G

Judge won't block Mississippi law on discounts for hospitals' contract pharmacies

Judge won't block Mississippi law on discounts for hospitals' contract pharmacies By Brendan Pierson July 1 (Reuters) - A federal judge in Mississippi on Monday refused to block a Mississippi law requiring drugmakers to offer discounts on drugs dispensed by third-party pharmacies that contract with hospitals and clinics serving low-income populations.
N

Foreign banks target Switzerland after UBS takeover of Credit Suisse

Foreign banks target Switzerland after UBS takeover of Credit Suisse By Oliver Hirt and Noele Illien ZURICH, June 24 (Reuters) - As Credit Suisse fades into history following its takeover by UBS last year, global banks are expanding in Switzerland to take advantage of companies' desire to spread their business. France's BNP Paribas BNPP.PA , Deutsche Bank DBKGn.DE and U.S.
B
C
D
N
N
U

Sarepta surges as investors cheer expanded use of gene therapy

UPDATE 2-Sarepta surges as investors cheer expanded use of gene therapy Adds background on FDA decision in paragraph 4, CEO quote in paragraphs 8 & 9, analyst quote in paragraph 12 & 13 By Mariam Sunny and Bhanvi Satija June 21 (Reuters) - Sarepta Therapeutics SRPT.O shares surged as much as 40% to a more than three-year high on Friday as an expanded use approval cemented its dominant position in the gene therapy market for Duchenne muscular dystrophy (DMD).
N
P
T

Morphosys And Novartis Sign Delisting Agreement

BRIEF-Morphosys And Novartis Sign Delisting Agreement June 20 (Reuters) - MORPHOSYS AG MORG.DE : MORPHOSYS AND NOVARTIS SIGN DELISTING AGREEMENT AND INTEND TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS’ MINORITY SHAREHOLDERS MORPHOSYS AG - ACCEPTANCE PERIOD OF TAKEOVER OFFER AND STATUTORY TWO-WEEK ADDITIONAL ACCEPTANCE PERIOD ENDED ON MAY 13, 20
M
N

Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders

BRIEF-Novartis BidCo Germany plans merger squeeze-out of Morphosys minority shareholders June 20 (Reuters) - MORPHOSYS AG MORG.DE : NOVARTIS BIDCO GERMANY AG INTENDS TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS AG’S MINORITY SHAREHOLDERS NOVARTIS BIDCO GERMANY AG CONFIRMED THAT IT CURRENTLY HOLDS APPROXIMATELY 91.04% OF TOTAL MORPHOSYS AG SHARE
M
N

EU regulator requires secondary cancer risk warning for T therapies

UPDATE 3-EU regulator requires secondary cancer risk warning for CAR-T therapies Changes headline, adds background in paragraphs 3, 5 & 6 June 14 (Reuters) - The European health regulator said on Friday cancer cell therapies known as CAR-T treatments must include a written warning of an associated risk for secondary blood cancers in patients who use them and that patients should be monitored for life.
G
N

EU regulator mandates label updates on T cancer therapies

EU regulator mandates label updates on CAR-T cancer therapies June 14 (Reuters) - The European health regulator said on Friday product information for a class of cancer therapies known as CAR-T treatments would be required to highlight risk of secondary cancers in patients who use them, ending a five-month safety review. Reporting by Mariam Sunny i
G
N

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V

Swiss stocks - Factors to watch on June 10

Swiss stocks - Factors to watch on June 10 ZURICH/GDANSK, June 10(Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS * Roche ROG.S - European Commission approves Roche’s Alecensa * Barry Callebaut AG BARN.S - Places New EUR 700 Mln Denominated Bond * Dormakaba Holding AG DOKA.S - To Divest Its Sub-Saharan African Business * Metall Zug AG METN.S , METN.S - Announces Start of JV ANALYSTS' VIEWS BARRY CALLEBAUT AG BARN.S - BERENBERG RAISES TARG
N
N
R
S

Law firm defends work in $5.6 bln card fee case after disclosing fake claims

Law firm defends work in $5.6 bln card fee case after disclosing fake claims By Mike Scarcella June 7 (Reuters) - A law firm that earlier said it unknowingly submitted fake claims as part of a $5.6 billion settlement with Visa and MasterCard told a U.S. judge on Thursday that other parties had also submitted fraudulent material in the case. Responding to a request for more information from the Brooklyn judge overseeing the antitrust case, New York-founded Milberg Coleman Bryson Phillips Grossman
N
V

US judge orders probe of Novartis $30 mln settlement claims process

US judge orders probe of Novartis $30 mln settlement claims process By Brendan Pierson June 6 (Reuters) - A federal judge has ordered a probe of the claims distribution process in a $30 million settlement by Novartis NOVN.S with consumers and health plans in an antitrust class action over its hypertension drug Exforge, citing concerns about its integrity.
N

Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists

INSIGHT-Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists By Kirsty Needham, Andrew Silver SYDNEY/SHANGHAI, June 6 (Reuters) - Employees of drugmaker WuXi AppTec, under U.S. scrutiny for its links to the Chinese military, co-invented altitude sickness treatments with People's Liberation Army (PLA) scientists, according to public patent records and science papers reviewed by Reuters.
N

Novartis, Roche unit and others face Italy antitrust probe over eye drug

UPDATE 3-Novartis, Roche unit and others face Italy antitrust probe over eye drug Adds Biogen comment in last paragraph ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched an investigation into pharmaceutical companies including Novartis NOVN.S and Roche-controlled ROG.S Genentech for having potentially restricted competition in the sale of an eye drug.
B
N
R

Novartis and others face Italy antitrust probe over eye drug

Novartis and others face Italy antitrust probe over eye drug ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis NOVN.S , for having potentially restricted competition in the sale of a drug for eye conditions. Samsung Bioepis, Biogen, Genentech and Novartis, and some of their Italian, Dutch and UK units, allegedly coordinated their commercial strategies to delay the launch in Italy of Byooviz, a d
B
N
R

Cytokinetics rises; CEO confirms prior M&A interest in company

BUZZ-Cytokinetics rises; CEO confirms prior M&A interest in company ** Shares of drug developer Cytokinetics CYTK.O rise 9.5%to $53 ** CEO Robert Blum said at an industry conference that CYTK was engaged in strategic talks with potential partners for its experimental heart disease drug, aficamten, throughout 2023 ** CYTK was approached by one of the third parties with whom they had previously engaged with regarding acquisition of the company, Blum says ** Blum says CYTK's board was supportive of
N



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.